Protagonist transitions rusfertide NDA regulatory leadership to Takeda

Protagonist Therapeutics, Inc

Takeda to lead regulatory strategy and NDA preparation for rusfertide in polycythemia vera; transition underway.
Protagonist remains primarily responsible for clinical development activities through NDA filing.
Decision made under License and Collaboration Agreement dated January 31, 2024, as amended.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.